

### **Amendments to the Claims**

This listing of claims will replace all prior versions, and listings, of claims in the application.

### **Listing of Claims**

1. (currently amended) A method of treating obesity in a vertebrate animal comprising administering to the animal an effective amount of a ~~non-toxic~~, gut motility-regulating ~~amount of~~ [[a]] compound that is a trichothecene or derivative thereof, wherein the compound stimulates a fed pattern of gut motility in the animal.
2. (previously presented) The method of treating obesity according to claim 1, wherein the compound is a trichothecene or derivative thereof selected from the group consisting of DON; 3-acetyl DON; isopropylidene DON; isopropylidene-3-acetyl-DON; DON carbonate; 3-acetyl-DON carbonate; 3-acetyl-DON benzylidene acetal; and DON benzylidene acetal.
3. (previously presented) The method of treating obesity according to claim 2, wherein the compound is DON.
4. (previously presented) The method of treating obesity according to claim 1, wherein the compound is administered orally, parenterally, intravenously, intramuscularly, or intra-arterially.
5. (previously presented) The method of treating obesity according to claim 4, wherein the compound is administered orally.
6. (original) The method of treating obesity according to claim 1, wherein the vertebrate animal is selected from the group consisting of primates, swine, cattle, sheep, birds, horses, cats, dogs, and rodents.
7. (original) The method of treating obesity according to claim 1, wherein the vertebrate animal is a human.

8. (withdrawn) A method of stimulating fed pattern of gut motility in a vertebrate animal comprising administering to the animal a non-toxic, gut motility-regulating amount of a compound selected from the group consisting of a trichothecene or derivative thereof, a trichothecene analog, and a non-desensitizing agonist of the  $P_{2X1}$  receptor.
9. (withdrawn) The method of claim 8, wherein the compound is a trichothecene or derivative thereof is selected from the group consisting of DON; 3-acetyl DON; isopropylidene DON; isopropylidene-3-acetyl DON; DON carbonate; 3-acetyl-DON carbonate; 3-acetyl-DON benzylidene acetal; and DON benzylidene acetal.
10. (withdrawn) The method of claim 9, wherein the compound is DON.
11. (withdrawn) The method of claim 8, wherein the compound is administered orally, parenterally, intravenously, intramuscularly, or intra-arterially.
12. (withdrawn) The method of claim 8, wherein the compound is administered orally.
13. (withdrawn) The method of claim 8, wherein the animal is selected from the group consisting of primates, swine, cattle, sheep, birds, horses, cats, dogs, and rodents.
14. (withdrawn) The method of claim 8, wherein the vertebrate animal is a human.
15. (withdrawn) The method of claim 8, wherein the non-desensitizing agonist of the  $P_{2X1}$  receptor is an analog of ATP.
16. (withdrawn) A method of increasing weight in a vertebrate animal comprising administering to said animal an analog of ATP in an amount sufficient to inhibit fed pattern gut motor activity.

17. (withdrawn) The method of claim 16, wherein the analog of ATP is a desensitizing agonist or an antagonist of the P<sub>2X1</sub> purinoceptor.

18. (withdrawn) The method of claim 17, wherein the analog of ATP is selected from the group consisting of  $\alpha,\beta$ -methylene ATP and 2',3'-O-(2,4,6-trinitrophenyl)-ATP.

19. (withdrawn) A method of preventing fed pattern of gut motility in a vertebrate animal comprising administering to the animal an analog of ATP.

20. (withdrawn) The method of claim 19, wherein the analog of ATP is a desensitizing agonist or an antagonist of the P<sub>2X1</sub> receptor.

21. (withdrawn) The method of claim 20, wherein the analog of ATP is selected from the group consisting of  $\alpha,\beta$ -methylene ATP and TNP-ATP.

22. (withdrawn) A method of identifying a compound for treating obesity comprising determining whether the compound is capable of inducing fed pattern gut motor activity.

23. (withdrawn) The method of identifying a compound for treating obesity according to claim 22, wherein the compound is tested for the ability to induce fed pattern gut motor activity using an *in vitro* gut organ bath assay, an *ex vivo* gut organ assay, or an *in vivo* assay for gut organ motor activity.

24. (withdrawn) The method of claim 22, wherein the fed pattern gut motor activity induced by the compound is compared to the fed pattern gut motor activity induced by DON.

25. (withdrawn) A pharmaceutical composition for inducing fed pattern gut motor activity comprising:

(a) a compound selected from the group consisting of 4-deoxynivalenol; 3-acetyldeoxynivalenol; 3-hydroxy-12,13-epoxy-9-tricothecin-8-one-7,15 carbonate; 3-acetoxy-

12,13-epoxy-9-tricothecin-8-one-7,15 carbonate; 3-acetoxy-7,15-benzylidene-12,13-epoxy-9-tricothecin-8-one; 3-hydroxy-7,15-benzylidene-12,13-epoxy-9-tricothecin-8-one; 3-hydroxy-7,15-isopropylidene-12,13-epoxy-9-tricothecin-8-one; 3-acetoxy-7,15-isopropylidene-12,13-epoxy-9-tricothecin-8-one; and combinations thereof, and  
(b) a pharmaceutically acceptable carrier.

26. (withdrawn) The compound 3-hydroxy-7,15-isopropylidene-12,13-epoxy-9-tricothecin-8-one.

27. (withdrawn) The compound 3-acetoxy-7,15-isopropylidene-12,13-epoxy-9-tricothecin-8-one.

28. (withdrawn) The compound 3-hydroxy-12,13-epoxy-9-tricothecin-8-one-7,15 carbonate.

29. (withdrawn) The compound 3-acetoxy-12,13-epoxy-9-tricothecin-8-one-7,15 carbonate.

30. (withdrawn) The compound 3-acetoxy-7,15-benzylidene-12,13-epoxy-9-tricothecin-8-one.

31. (withdrawn) The compound 3-hydroxy-7,15-benzylidene-12,13-epoxy-9-tricothecin-8-one.

32. (withdrawn) A method of regulating food intake by a vertebrate animal comprising administering to the animal a compound selected from the group consisting of a tricothecene, a tricothecene derivative, and a non-desensitizing agonist of the  $P_{2X1}$  receptor; wherein the compound is effective to act non-toxically to stimulate a fed pattern of gut motility in the animal.

33. (withdrawn) The method of claim 32, wherein the compound is a tricothecene or tricothecene derivative selected from the group consisting of DON; 3-acetyl DON; isopropylidene DON; isopropylidene-3-acetyl DON; DON carbonate; 3-acetyl-DON carbonate; 3-acetyl-DON benzylidene acetal; and DON benzylidene acetal.

34. (withdrawn) The method of claim 33, wherein the compound is DON.
35. (withdrawn) The method of claim 32, wherein the compound is administered orally, parenterally, intravenously, intramuscularly, or intra-arterially.
36. (withdrawn) The method of claim 35, wherein the compound is administered orally.
37. (withdrawn) The method of claim 32, wherein the vertebrate animal is selected from the group consisting of primates, swine, cattle, sheep, birds, horses, cats, dogs, and rodents.
38. (withdrawn) The method of claim 32, wherein the vertebrate animal is a human.
39. (withdrawn) The method of claim 32, wherein the non-desensitizing agonist of the  $P_{2X1}$  receptor is an analog of ATP.